Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis

Neuroblastoma is a heterogeneous tumour and its effective clinical management is dependent on accurate prognostic evaluation. In approximately 25% of patients amplification of the MYCN oncogene is known to be associated with a poor outcome. In order to identify additional molecular markers with prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Luttikhuis, M E M Oude, Powell, J E, Rees, S A, Genus, T, Chughtai, S, Ramani, P, Mann, J R, McConville, C M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364087/
https://www.ncbi.nlm.nih.gov/pubmed/11506492
http://dx.doi.org/10.1054/bjoc.2001.1960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364087/
https://www.ncbi.nlm.nih.gov/pubmed/11506492
http://dx.doi.org/10.1054/bjoc.2001.1960

Ejemplares similares